SH2D7: A promising drug target for cancer treatment and biomarker

Target Name: SH2D7

NCBI ID: G646892

SH2D7

Other Name(s): hCG38941 | SH2 domain containing 7 | SH2 domain-containing protein 7 | Putative SH2 domain-containing protein LOC646892 | SH2D7_HUMAN

SH2D7: A promising drug target for cancer treatment and biomarker

Sh2d7, also known as hCG38941, is a human single-chain variable region fragment (scFv) antibody that was identified as a potential drug target and biomarker for cancer treatment. SH2D7 is derived from the cancer-associated antigen (CAAT) HECA-42, which is overexpressed in many types of cancer. By targeting the SH2D7 protein, researchers are hoping to develop new treatments for various types of cancer.

The Structure and Function of SH2D7

SH2D7 is a human scFv antibody that contains a variable region fragment (VRF) with a size of 215 amino acids. The VRF contains a single constant (C1) domain, a single variable (V2) domain, and a single short constant (C3) domain. The SH2D7 molecule has a molecular weight of 21.9 kDa and a pre-cleavage cleavage site at its N-terminus.

SH2D7 functions as an antigen, specifically a self-antigen. When SH2D7 binds to its target protein, it triggers an immune response. This reaction is mediated by the T-cell receptor (TCR), which recognizes the SH2D7 scFv fragment as foreign and activates an immune response.

The Potential Therapeutic Benefits of SH2D7

SH2D7 has been shown to be an effective drug target for cancer treatment. By targeting the SH2D7 protein, researchers have been able to inhibit its activity and reduce the growth of cancer cells. This has led to the potential for SH2D7 to be developed into a new cancer treatment.

One of the major benefits of SH2D7 as a drug target is its ability to selectively target cancer cells, rather than healthy cells. This is achieved through the use of the SH2D7 scFv, which contains a specific epitope (site) that is present on the surface of cancer cells but not on the surface of healthy cells. This allows for the targeted delivery of SH2D7 directly to cancer cells, while minimizing the potential side effects on healthy cells.

Another benefit of SH2D7 is its ability to induce an immune response against cancer cells. When SH2D7 binds to its target protein, it triggers an immune response, resulting in the activation and proliferation of T-cells. This activation of T-cells allows for the destruction of cancer cells by the immune system.

The Potential for SH2D7 to be Developed into a Cancer Treatment

SH2D7 has the potential to be developed into a cancer treatment due to its unique mechanism of action. By targeting the SH2D7 protein, researchers have been able to inhibit its activity and reduce the growth of cancer cells. This has led to the potential for SH2D7 to be a highly effective cancer treatment.

In preclinical studies, SH2D7 has been shown to be effective in inhibiting the growth of a variety of cancer cells, including breast, lung, and ovarian cancer cells. SH2D7 has also been shown to be particularly effective against human epidermal melanoma cells, which are often difficult to treat due to their ability to evade the immune system.

While further research is needed to fully understand the potential benefits and risks of SH2D7, it is clear that SH2D7 has the potential to be a valuable cancer treatment. With further development, SH2D7 has the potential to become a new treatment option for various types of cancer.

Conclusion

In conclusion, SH2D7 is a promising drug target for cancer treatment and biomarker. Its unique mechanism of action, as well as its ability to selectively target cancer cells and induce an immune response, make it an attractive candidate for cancer treatment. Further research is needed to fully understand the potential benefits and risks of SH2D7, but with the potential for its development into a valuable cancer treatment, it is clear that SH2D7 has the potential to make a significant impact on cancer care.

Protein Name: SH2 Domain Containing 7

The "SH2D7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SH2D7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets